PER-012-15尚未招募未知
EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Key inclusion criteria (See Section 3.3.1 for the full list of criteria):
- •a) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- •b) Histologically confirmed malignant melanoma, including mucosal melanoma
- •c) Previously treated unresectable stage III or stage IV melanoma, as per American Joint Committee on
- •Cancer staging system regardless of BRAF mutation status
- •d) Progressed on or after treatment with an anti-CTLA-4-containing therapy. Prior treatment with other
- •therapies is permitted (eg, chemotherapy)
- •i) Subjects with BRAF mutation positive advanced melanoma must also have progressed on or after
- •treatment with BRAF inhibitor monotherapy or in combination with a MEK inhibitor
排除标准
- •Key exclusion criteria (See Section 3.3.2 for the full list of criteria)
- •a) Active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 2 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. There must also be no requirement for high doses of systemic corticosteroids that could result in immunosuppression (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
- •b) Subjects with ocular melanoma
- •c) Life expectancy < 6 weeks
- •d) Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment or conditions not expected to recur in the absences of an external trigger are permitted to enroll.
- •e) Subjects with a known history of the following anti-CTLA-4 therapy related adverse reactions based on the CTCAE v criteria:
- •i) Grade 4 anti-CTLA-4 therapy related adverse reaction except resolved nausea, fatigue, infusion
- •reactions or endocrinopathies where clinical symptoms were able to be controlled with appropriate hormone replacement therapy
- •ii) Grade 3 anti-CTLA-4 therapy related adverse reactions must have resolved or been controlled within 12 weeks
- •iii) Any ≥Grade 2 eye pain or reduction of visual acuity that did not respond to topical therapy and did not improve to ≤ Grade 1 severity within 2 weeks of starting topical therapy or required systemic treatment
- •iv) Any ≥Grade 3 sensory neurologic toxicity
- •v) Any Grade 4 laboratory abnormalities, except AST, ALT or T. bilirubin:
- •(1) AST or ALT > 10 x ULN
- •(2) T. bilirubin > 5 x ULN
- •vi) Subjects who required infliximab or other immune suppressants including mycophenolic acid for management of drug related toxicities
- •vii) History of Grade ≥3 neurologic toxicity
- •viii) History of Grade ≥3 allergy to study drug components.
- •f) Any treatment in a nivolumab trial
研究者
相似试验
招募中
Unknown
Expanded Access Program with Nivolumab (ONO-4538) for malignant non-pleural mesothelioma (VIOLA)Malignant MesotheliomaNivolumabMesotheliomaJPRN-jRCT2051220186Kijima Takashi15
已完成
不适用
Expanded Access Program to provide Nusinersen to Patients with infantile-onset spinal muscular atrophy (SMA)G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]DRKS00011547Klinik für Neuropädiatrie und MuskelerkrankungenZentrum für Kinder- und JugendmedizinUniversitätsklinikum Freiburg61
进行中（未招募）
不适用
ivoCUP-2JPRN-jRCT2051200146akagawa Kazuhiko60
No Longer Available
不适用
Expanded Access Program With Nivolumab to Treat MelanomaStage III (Unresectable) or Stage IV Advanced MelanomaNCT02142218Bristol-Myers Squibb
进行中（未招募）
1 期
Expanded access program for mepolizumab in subjects with HESSubjects with life-threatening HESMedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2007-000838-39-GBGlaxoSmithKline Research & Development Ltd200